Clinical trials: Human Cancers
Prostate Cancer
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of BNT112 cancer vaccine (BNT112) monotherapy or in combination with cemiplimab…
- Trial name
- PRO-MERIT (NCT04382898)
- Testing
- BNT112, Cemiplimab
- Where
- 22 sites in United States, Germany and 2 more
- Volunteers
- 75 people
- Sponsor
- BioNTech SE
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Lymphoma, Non-Hodgkin
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) [Part A: Dose Escalation] and to further assess the safety of…
- Trial name
- NCT06139406
- Testing
- JNJ-87801493, JNJ-80948543, JNJ-75348780
- Where
- 12 sites in Australia, Denmark and 2 more
- Volunteers
- 70 people
- Sponsor
- Janssen Research & Development, LLC
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination…
- Conditions
- Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06827236
- Testing
- BNT323, BNT327
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 380 people
- Sponsor
- BioNTech SE
Human Papilloma Virus, HIV Infections
ERADICATING CERVICAL CANCER IN KENYA
This is a study of a strategy designed to 1) increase cervical cancer screening using a community-based approach, and 2) determine the efficacy of HPV vaccination in a region of Kenya where half of all children are chronically…
- Trial name
- NCT04774887
- Testing
- HPV vaccine, Merck
- Where
- Kenya
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Indiana University
Breast Cancer
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.
- Trial name
- NCT06452706
- Testing
- TQB2102 for injection
- Where
- 16 sites in China
- Volunteers
- 42 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Lung Adenocarcinoma, Ovarian Cancer
CAR T Cells in Mesothelin Expressing Cancers
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
- Conditions
- Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03054298
- Testing
- huCART-meso cells
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pennsylvania
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections
A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV)
This is a non-randomized, open label study to assess the reduction of Human Papillomavirus (HPV) infectivity and transmission in women positive for HPV16 and/or 18 in a cervical, oral and anal sample and vaccinated with…
- Conditions
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV, HPV-16/ 18
- Trial name
- RIFT-HPV (NCT05334706)
- Testing
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
- Where
- Spain
- Volunteers
- 69 people
- Sponsor
- Miquel Angel Pavon Ribas
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer, Malignant Melanoma
Efficacy Study of IL-21 to Treat Metastatic Melanoma
This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At least 14 to a maximum of 40 patients, who have not previously received treatment for their stage IV disease, will be treated for 6 weeks.
- Trial name
- NCT00336986
- Testing
- recombinant interleukin-21
- Where
- 7 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Advanced Solid Tumor
Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours
This is the 'first-in-human' clinical trial of the Investigational Medicinal Product (IMP), Tablet formulation for Oral dosing of MSP008-22, a molecule (new chemical entity) with anticancer properties.
- Trial name
- NCT05478486
- Testing
- MSP008-22
- Where
- India
- Volunteers
- 7 people
- Sponsor
- Godavari Biorefineries Limited
EBV
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
This is a Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
- Trial name
- NCT07557602
- Testing
- VXCO-102
- Where
- 2 sites in Australia
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- NCT06611553
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This Phase IIIb, open-label, multinational, multicenter study will evaluate the participant's satisfaction and safety with subcutaneously administered trastuzumab in participants with HER2-positive early breast cancer.
- Trial name
- NCT01964391
- Testing
- Trastuzumab, Doxorubicin, Cyclophosphamide
- Where
- 23 sites in Algeria, Morocco and 3 more
- Volunteers
- 174 people
- Sponsor
- Hoffmann-La Roche
Relapsed Advanced Lymphomas
Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma
A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR112 in Patients with Relapsed Advanced Lymphoma (ADITI-1)
- Trial name
- ADITI-1 (NCT06755450)
- Testing
- AUR112
- Where
- 19 sites in India
- Volunteers
- 40 people
- Sponsor
- Aurigene Discovery Technologies Limited
HIV Infections, Oral Squamous Cell Carcinoma
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
This is an exploratory qualitative study among People Living With HIV (PLWH) of diverse racial/ethnic and sexual and gender minority (SGM) identities to explore individual, interpersonal, and structural oral health equity factors…
- Conditions
- HIV Infections, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT06055868
- Testing
- Group Meeting (Focus Group), Questionnaires
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- University of California, San Francisco
HPV Infection, Health Behavior
HPV Vaccination Health-promotion Programme on Vaccine Acceptance and Uptake Among Female Adolescents
The MDL-SHPVP will be developed and a clustered randomised controlled trial will be conducted to evaluate the effects of the MDL-SHPVP and to examine whether the effect of the MDL-SHPVP on the rate of HPV vaccine uptake 1 year…
- Conditions
- HPV Infection, Health Behavior, Health Attitude
- Trial name
- NCT04438291
- Testing
- MDL-SHPVP, 30-minute educational video
- Where
- Hong Kong
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Breast Cancer
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
The purpose of the study was to evaluate the safety and efficacy of a reduced ribociclib starting dose of 400 mg in combination with a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) for the treatment of pre…
- Trial name
- AMALEE (NCT03822468)
- Testing
- Ribociclib, Anastrozole, Letrozole
- Where
- 89 sites in United States, Argentina and 21 more
- Volunteers
- 376 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c
Recombinant human GM-CSF herpes simplex virus injection (OrienX010) is a genetically engineered from Chinese patients oral separation of wild type 1 herpes simplex virus (HSV) as the carrier insert GM-CSF gene therapy drug.After…
- Trial name
- NCT03048253
- Testing
- OrienX010
- Where
- China
- Volunteers
- 30 people
- Sponsor
- OrienGene Biotechnology Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.